Keytruda (Pembrolizumab) Information for China
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
This article provides information on the availability and regulatory status of Keytruda (pembrolizumab) in China. Pembrolizumab is an anti-PD-1 immune checkpoint inhibitor developed by Merck and approved for a wide range of cancer types including lung cancer, melanoma, gastric cancer, cervical cancer, and others. Patients in China seeking access to Keytruda or looking for treatment options at Japanese medical institutions can contact Medical Supporter for assistance with cross-border medical coordination.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4